Connect Sign InMutations, Biomarkers, and Pathways: A Molecular Tour of Gastrointestinal Cancer
This presentation will provide an overview of key molecular biomarkers that play a crucial role in the diagnosis, prognosis, and treatment of colon, gastric, and esophageal cancers. It will explore the latest advancements in biomarker discovery, highlighting their clinical utility. Attendees will gain insights into the molecular pathways driving these cancers and the implications of biomarkers such as microsatellite instability, HER2, and PD-L1 in guiding treatment decisions and improving patient outcomes.
Originally published on February 4, 2026.
Dr. Cameron Beech is a medical director of Solid Tumor Molecular Oncology at ARUP Laboratories, and an assistant professor (clinical) for the University of Utah School of Medicine. He received his medical degree from the University of Toledo College of Medicine and did his residency in anatomic and clinical pathology at Yale New Haven Hospital. He completed fellowships in oncologic surgical pathology and molecular genetic pathology at Memorial Sloan Kettering Cancer Center and gastrointestinal, pancreatic, and hepatobiliary pathology at Yale New Haven Hospital. Dr. Beech is board certified in anatomic and clinical pathology and molecular genetic pathology by the American Board of Pathology. His research interests include application of next generation sequencing to solid tumors and genomic alteration in gastrointestinal malignancies.
